ImmuneSense Lyme Study

Inclusion Criteria: Cohort 1: * Participants at or above the age of 7 * Arm A: Participants with an EM rash ≥ 5 cm (confirmed by Lyme disease independent expert) with or without other signs and symptoms of Lyme disease * Arm B: Participants who do not have an EM rash \>/= 5 cm (either not confirmed by a Lyme disease independent expert or lacking a rash), but who have signs and symptoms suggestive of Lyme disease that warrants further testing, such as, but not limited to fever, myalgias, malaise, lymphadenopathy, rigors, arthralgias, peripheral and radiculoneuropathy, encephalopathy, intermittent arthritis, meningitis, heart block, carditis, etc Cohort 2: \- Individuals in general good health, who reside in Lyme disease endemic regions Cohort 3: \- Individuals in general good health, who reside in a region that is non-endemic for Lyme disease Cohort 4: Sourced from a sample repository * Biorepositories with documented consent from participants for secondary use of their sample by a third party * Confirmed, documented diagnoses for one of the following diseases: * Viral: Epstein-Barr virus (EBV), cytomegalovirus (CMV), influenza, or COVID-19 * Tick-borne diseases: babesiosis, rocky mountain spotted fever, anaplasmosis, or ehrlichiosis * Bacterial infection: syphilis * Autoimmune/rheumatologic/neurologic diseases: Systemic Lupus Erythematous (SLE), Rheumatoid Arthritis (RA), Multiple Sclerosis (MS), chronic fatigue syndrome * For infections, active infections are prefer…